Cardiff Oncology, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors Nominees: Dr. James O. Armitage

Cardiff Oncology, Inc.’s own tally for this item (“Elect Director: Dr. James O. Armitage”): 18,806,657 for, 0 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 844,159 for, 5,678 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Dr. Rodney Markin

Cardiff Oncology, Inc.’s own tally for this item (“Elect Director: Dr. Rodney Markin”): 18,647,050 for, 0 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 843,530 for, 6,308 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Gary W. Pace, Ph.D.

Cardiff Oncology, Inc.’s own tally for this item (“Elect Director: Gary W. Pace, Ph.D.”): 18,877,743 for, 0 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 843,953 for, 5,884 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Lale White

Cardiff Oncology, Inc.’s own tally for this item (“Elect Director: Lâle White”): 18,710,040 for, 0 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 849,837 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Mani Mohindru, Ph.D.

Cardiff Oncology, Inc.’s own tally for this item (“Elect Director: Mani Mohindru, Ph.D.”): 18,942,979 for, 0 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 849,414 for, 424 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Election of Directors Nominees: Renee P. Tannenbaum, Pharm.D.

Cardiff Oncology, Inc.’s own tally for this item (“Elect Director: Renee P. Tannenbaum, Pharm.D.”): 18,790,068 for, 0 against, per its Form 8-K filed June 11, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “All of the six (6) nominees for director were elected to serve until the 2027 Annual Meeting of Stockholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death.”
Support: 100% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 843,736 for, 6,102 withheld.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.

Description as filed by funds: Proposal to approve an amendment to the Company's 2021 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares from 12,150,000 shares.

Cardiff Oncology, Inc.’s own tally for this item (“3. An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares”): 10,740,460 for, 8,063,520 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “An amendment to the Company's 2021 Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares was approved by the stockholders by the votes set forth in the table below:”
Support: 57% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 33 asset managers below reported 305,058 for, 546,779 against.

Showing the 25 largest of 33 asset managers. See all 33 in the interactive database.

Description as filed by funds: Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers.

Cardiff Oncology, Inc.’s own tally for this item (“4. Advisory vote on the compensation of the Company's named executive officers”): 17,120,176 for, 1,772,185 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The advisory vote on the compensation of the Company's named executive officers was approved by the stockholders by the votes set forth in the table below:”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 32 managers: 849,699 for, 138 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 88 managers: 9,797,306 for, 8,301 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Proposal to ratify the appointment of BDO USA, P.C. as the Company's independent registered public accountants for fiscal year ending December 31, 2026.

Cardiff Oncology, Inc.’s own tally for this item (“2. Appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2026”): 40,239,508 for, 1,070,807 against — passed, per its Form 8-K filed June 11, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for its fiscal year ended December 31, 2026 was ratified and approved by the stockholders by the votes set forth in the table below:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 32 asset managers below reported 849,837 for.

Showing the 25 largest of 32 asset managers. See all 32 in the interactive database.